Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

AbbVie’s Humira loss of exclusivity a missed opportunity for competitors, says GlobalData

AbbVie‘s market leadership, driven by its flagship disease-modifying antirheumatic drug Humira (adalimumab), faced a significant test with the 2023 loss of patent protection. Despite an anticipated competitive surge, rivals have struggled to capitalize. AbbVie’s strategic shift to Skyrizi (risankizumab) and Rinvoq (upadacitinib) has solidified its position, underscoring a missed opportunity for competitors in the immunology […]
Read more

Diagnosed prevalent cases of chronic kidney disease to reach 22.97 million across 7MM in 2033, predicts GlobalData

The diagnosed prevalent cases of chronic kidney disease (CKD) across the seven major markets (*7MM) are projected to increase at an annual growth rate (AGR) of 0.90% from 21.08 million in 2023 to 22.97 million in 2033, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “Chronic Kidney Disease: Epidemiology Forecast to 2033,” […]
Read more

Synergistic safety profile could increase sublingual apomorphine competitiveness, says GlobalData

Sublingual apomorphine (SL-APO) is a dopamine agonist (DA) marketed by Bial under the brand name Kynmobi in several countries for the on-demand treatment of levodopa wear-off (OFF-episodes) that are not sufficiently controlled by levodopa “add-on” (adjunct) therapies. At the 10th Congress of the European Academy of Neurology (EAN) 2024, Dr. Diego Santos García presented a […]
Read more

Opicapone demonstrates efficacy in real-world clinical practice, says GlobalData

Opicapone is a catechol-O-methyltransferase (COMT) inhibitor marketed in several countries by either Amneal Pharmaceuticals or Bial, depending on region, under the brand name “Ongentys” for the treatment of levodopa wear-off in Parkinson’s disease (PD). At the 10th Congress of the European Academy of Neurology (EAN) 2024, Dr. Maria-Rosario Luquin and Dr. Lydia López Manzanares separately […]
Read more

Safinamide outperforms rasagiline in efficacy, cost-efficacy, and forecasted sales, says GlobalData

Safinamide is a monoamine oxidase B (MAO-B) inhibitor marketed in several countries under the brand name Xadago by Newron Pharmaceuticals for the treatment of levodopa wear-off in Parkinson’s disease (PD). At the 10th Congress of the European Academy of Neurology (EAN) 2024, Dr. Ester Morales García presented a pharmacoeconomic report comparing safinamide to its competitor […]
Read more

Prioritized investments from pharma companies shaping competitive pipeline landscape of bronchiectasis, says GlobalData

Recent studies have allowed the unexplored field of bronchiectasis to be further investigated by shedding light on the mechanisms behind the disease’s pathophysiology. In recent years, bronchiectasis has garnered a significant amount of attention, with pharmaceutical companies prioritizing their investments in the development of promising pipeline agents to treat the disease through various mechanisms of […]
Read more

Healey platform data to pave phase III path for Prilenia’s pridopidine, says GlobalData

Developing disease-modifying treatments for amyotrophic lateral sclerosis (ALS), a rare and aggressive disease, has proven challenging. The high failure rate in ALS clinical trials is often attributed to the disease’s unclear etiology and complex pathophysiology. At the 10th Congress of the European Academy of Neurology (EAN) 2024, Prilenia Therapeutics presented promising results from the additional […]
Read more

Ajovy benefits diminish with migraine treatment cessation and re-initiation, says GlobalData

The interim results from the observational, prospective Phase IV Pan-European Real-Life (PEARL) study, presented at the 10th Congress of the European Academy of Neurology, indicate that treatment cessation and re-initiation can reduce the benefits of Teva Pharmaceutical’s Ajovy for migraine management. Continuous administration of Ajovy is crucial for effective prevention, challenging current guidelines that recommend […]
Read more

Preventative treatment of chronic migraine will continue to evolve in short-term with anti-CGRP mAbs effectiveness, says GlobalData

OnabotulinumtoxinA (BoNT-A) and monoclonal antibodies against the calcitonin gene-related protein (anti-CGRP mAbs) have emerged as the first disease-specific preventative treatments to be approved for chronic migraine. At the 10th Congress of the European Academy of Neurology (EAN) 2024, Danilo Antonio Montisano, MD, presented real-world evidence findings from a retrospective, observational multicenter cohort study (RAMO) comparing […]
Read more

VNS and cenobamate combo therapy success paves way for cenobamate monotherapy, says GlobalData

At the recently held 10th Congress of the European Academy of Neurology (EAN), two investigator-led ePresentation sessions on epilepsy outlined the effectiveness of a combination of a new anti-seizure medication (ASM), Xcopri (cenobamate) and vagus nerve stimulation (VNS) in managing drug-resistant epilepsy (DRE). The combination therapy demonstrated significant improvements in seizure control, highlighting its potential […]
Read more

EMA approval of Sanofi/Regeneron’s Dupixent fills biologic gap in COPD, says GlobalData

Following the European Medicines Agency (EMA) approval of Sanofi/Regeneron’s Dupixent (Dupilumab) on 03 July 2024: Asiyah Nawab, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Dupixent, a monoclonal antibody (mAb) targeting interleukin-4 (IL4) and interleukin-13 (IL13) pathways, has been approved by the EMA as the first biologic for uncontrolled chronic […]
Read more

Total prevalent cases of female infertility to decrease at 0.4% AGR in 7MM during 2023-33, forecasts GlobalData

The total prevalent cases of female infertility in the seven major markets (*7MM) are projected to decrease from 16,732,165 cases in 2023 to 16,053,363 cases in 2033, registering a negative annual growth rate (AGR) of 0.41%, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “Female Infertility – Epidemiology Analysis and Forecast to […]
Read more

Eli Lilly’s Kisunla approval to heat up competition in the Alzheimer’s market, says GlobalData

Following the news that the FDA has approved Eli Lilly’s anti-amyloid beta (Aβ) monoclonal antibody (mAb) Kisunla (donanemab) for the treatment of patients with mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD); Philippa Salter, Managing Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “After facing several delays, Lilly’s Kisunla […]
Read more

Amylyx looks to cover financial gap left by Relyvrio with avexitide deal, says GlobalData

In June, Amylyx Pharmaceuticals acquired the rights to Eiger Biopharmaceuticals’ experimental glucagon-like peptide-1 (GLP-1) receptor antagonist, avexitide, for $35.1 million. Avexitide was previously developed for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). The acquisition is a notable strategic action by Amylyx following the failure of its lead amyotrophic lateral sclerosis (ALS) therapy, Relyvrio (sodium phenylbutyrate […]
Read more

Asthma inhaler price cap in US may help pharma companies to secure more loyal customer base, says GlobalData

In the US, a recent initiative by major pharmaceutical companies to cap the cost of asthma inhalers at $35 per month marks a significant development in healthcare affordability and accessibility. Overall, the price cap on asthma inhalers represents a multifaceted victory. For patients, it means improved access to life-saving medications and a reduction in financial […]
Read more

FDA approval of Verona’s Ohtuvayre to transform US COPD market for severe exacerbators, says GlobalData

Following the Food and Drug Administration’s (FDA) approval of Verona Pharma’s Ohtuvayre (ensifentrine) yesterday evening in the US: Asiyah Nawab, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Ohtuvayre, a first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor, has great potential to dominate the market for moderate to severe exacerbators with chronic […]
Read more
1 … 18 19 20 21 22 … 110